Cash/Burn From SEC Filing For Period: 

Q1 '20

AGEN

Agenus Inc.

The company’s I-O portfolio is comprised of checkpoint antibodies, cell therapies, vaccines, and adjuvants, representing a combination of synergistic agents to deliver curative patient outcomes

Cash

$92.3M

Burn Rate

$45M

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

Refractory Cervical Cancer

BLA filing

TBD

AGEN1181

Advanced endometrial cancer

Phase 1

TBD

Allogenic iNKTs

COVID-19

Phase 1 Trial

TBD

Allogenic iNTKs

Cancer

Phase 1

TBD

AGEN1327

Cancer

IND Submission

December 2020 (Est)

AGEN 1777

Cancer

IND Submission

December 2020 (Est)

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon